Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 14, 2026
TickeronGET DAILY SIGNALS
Global X HealthTech ETF (HEAL): Steady Performance in Digital Health Amid Modest +2% Monthly Gains

Global X HealthTech ETF (HEAL): Steady Performance in Digital Health Amid Modest +2% Monthly Gains

Key Takeaways

  • The Global X HealthTech ETF (HEAL) is a passive, index-tracking thematic ETF focused on digital health and health technology companies.
  • The fund holds roughly 40 positions spanning health software, telehealth, medical devices, and diagnostics, with top holdings including Veeva Systems (VEEV), IQVIA (IQV), Oscar Health (OSCR), and DexCom (DXCM).
  • HEAL has moved only modestly over the past 30 days, advancing roughly 2%, leaving it in a gradual, range-bound pattern rather than a sharp trend.
  • Over the trailing three-month period, the fund has risen approximately 3%, reflecting steady but unspectacular momentum in health-technology equities.
  • Sector exposure is essentially 100% healthcare, with meaningful weight in health information services, medical devices, and consumer-facing telehealth.
  • For a deeper look at the fund's valuation levels and projections, review its Price Targets and Forecast on dedicated pages.
  • Investors seeking automated, data-driven ideas may also explore Trending AI Robots.

Global X HealthTech ETF (HEAL) at a Glance

The Global X HealthTech ETF seeks to track the Global X HealthTech Index, offering targeted exposure to companies developing or commercializing digital health technologies. Launched in 2020 and sponsored by Global X, the fund is a passive, non-diversified, index-tracking product rather than an actively managed strategy. Its investment universe blends health information services, medical devices and diagnostics, telehealth, and consumer health platforms.

The portfolio holds roughly 40 securities and carries an expense ratio of 0.50%. Its asset base is small, with assets under management (AUM) of approximately $30 million, a structural characteristic that can translate into wider bid-ask spreads and thinner trading liquidity relative to larger peers. Top positions include Veeva Systems (VEEV), IQVIA (IQV), Oscar Health (OSCR), DexCom (DXCM), ResMed (RMD), GE HealthCare (GEHC), Tempus AI (TEM), and Hims & Hers Health (HIMS). Geographically, the fund is predominantly North American, supplemented by European, Australian, and Asian listings such as Pro Medicus, Koninklijke Philips, and Demant. I also checked this using Tickeron’s AI Screener to see how the holdings compare across the sector.

Industry and Thematic Landscape

HEAL sits at the intersection of healthcare and technology, a theme shaped by several durable forces. The integration of artificial intelligence into drug development, clinical workflows, and revenue-cycle management has reinforced demand for data and software providers such as Veeva Systems (VEEV), IQVIA (IQV), and Tempus AI (TEM). Simultaneously, the rise of wearable and continuous glucose-monitoring devices has supported diagnostics and device franchises, while direct-to-consumer telehealth platforms have expanded access to care and prescription services.

The broader macroeconomic environment remains a key influence. As growth-oriented and often small- to mid-capitalization companies, many health-technology constituents are sensitive to interest-rate expectations and investor risk appetite. Healthcare spending trends, reimbursement policy, and the rapid adoption of GLP-1 weight-loss therapies also continue to reshape both the delivery and the economics of care, creating headwinds for some legacy device categories while opening new demand for personalized and data-driven treatment models. From what I see, these dynamics warrant close attention when evaluating the fund's positioning.

Performance and Positioning Snapshot

Over the trailing 30 days, HEAL has advanced about 2%, while its three-month move is approximately 3%. The fund has traded in a measured, range-bound fashion: after dipping toward the high-$27 level in early August, it climbed above $31 in late October before easing back to roughly $30. This pattern points to gradual accumulation and periodic profit-taking rather than a sustained directional breakout. I also checked this using Tickeron’s AI Trend Prediction Engine to assess recent momentum signals.

The performance has been driven largely by the fund's largest holdings. Strength in consumer-facing telehealth and pharmacy names, wearable glucose-monitoring providers, and health-information-services companies has provided support, while the fund's exposure to smaller, higher-multiple growth stocks has kept volatility elevated relative to broad market benchmarks. Because healthcare represents effectively the entire portfolio, HEAL's behavior closely tracks health-technology subsector sentiment rather than providing diversified sector protection.

2026 Outlook and Key Factors to Monitor

Several structural factors are likely to shape HEAL over the balance of 2026. The trajectory of interest rates and inflation will influence how investors value the growth-oriented, often unprofitable companies that populate this portfolio. The pace of AI adoption across clinical, research, and administrative functions represents both an opportunity and a competitive risk for incumbent software providers. Developments in GLP-1 therapies, telehealth reimbursement rules, and healthcare regulation could shift demand across the fund's device, services, and consumer-health holdings.

Capital flows into thematic and small-cap ETFs, along with consolidation and M&A activity in digital health, may further affect positioning. Investors should also weigh the fund's modest AUM and trading liquidity, which can amplify transaction costs and, in extreme cases, elevate closure risk. These themes, rather than any single data point, are likely to determine the fund's performance environment in the months ahead.

Exploring Tickeron AI Tools for Deeper Analysis

In my own research process, I often turn to Tickeron’s AI Screener when evaluating thematic ETFs like this one. It helps surface comparable opportunities across health technology and related sectors by combining technical indicators, fundamentals, and AI-generated signals into a single workflow. This approach has proven useful for identifying patterns that align with the fund’s holdings and broader industry trends without replacing traditional due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HEAL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HEAL's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for HEAL moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 20 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HEAL as a result. In 77 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for HEAL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HEAL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

HEAL broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

HEAL moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where HEAL advanced for three days, in 243 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 174 of 212 cases where HEAL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), IQVIA Holdings (NYSE:IQV), Teladoc Health (NYSE:TDOC).

Industry description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Global X HealthTech Index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of healthcare technology and the applications thereof, as determined by the index administrator. The principal investment strategy of the fund will be to invest at least 80% of its total assets, plus borrowings for investment purposes (if any), in the securities of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Global X HealthTech ETF (HEAL) ETF is 18.05B. The market cap for tickers in the group ranges from 1.18B to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is TNDM at 1.18B.

High and low price notable news

The average weekly price growth across all stocks in the Global X HealthTech ETF (HEAL) ETF was -2%. For the same ETF, the average monthly price growth was 2%, and the average quarterly price growth was 25%. TNDM experienced the highest price growth at 19%, while HIMS experienced the biggest fall at -24%.

Volume

The average weekly volume growth across all stocks in the Global X HealthTech ETF (HEAL) ETF was -28%. For the same stocks of the ETF, the average monthly volume growth was -13% and the average quarterly volume growth was -56%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 62
Price Growth Rating: 44
SMR Rating: 67
Profit Risk Rating: 92
Seasonality Score: 28 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
Alphabet (GOOGL) fell roughly 15.3% over the last 30 days, sliding from about $349.22 to $295.77, driven primarily by a post-earnings selloff. The decline followed Alphabet's Q3 2026 results, when earnings per share of $2.12 badly missed the $3.02 consensus estimate.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
Global X HealthTech ETF (HEAL): Steady Performance in Digital Health Amid Modest +2% Monthly Gains